Sage changes main end­point in Hunt­ing­ton's study months ahead of read­out

Sage Ther­a­peu­tics is al­ter­ing the pri­ma­ry end­point of a Phase 2 study for its drug can­di­date dalzanem­dor in cog­ni­tive im­pair­ment as­so­ci­at­ed with Hunt­ing­ton’s dis­ease, just …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER